Liberty Capital Management Inc. Invests $3.14 Million in Abbott Laboratories $ABT

Key Points

• Liberty Capital Management acquired 34,602 Abbott Laboratories shares worth approximately $3.14 million in the second quarter. Institutional investors collectively own 75.18% of Abbott’s stock.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $118.67, despite some recent target reductions.
• Abbott beat quarterly earnings and revenue expectations, reporting $1.31 in EPS and $12.59 billion in revenue, while revenue increased 13% year over year. The company also pays a $0.63 quarterly dividend, yielding about 2.3% annually.

Liberty Capital Management Inc. acquired a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 34,602 shares of the healthcare product maker's stock, valued at approximately $3,140,000.

A number of other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock valued at $648,000 after acquiring an additional 162 shares in the last quarter. United Bank raised its position in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after acquiring an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC lifted its holdings in shares of Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its position in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after purchasing an additional 292,547 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ABT shares. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. Barclays decreased their price objective on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research note on Monday, April 20th. Leerink Partners dropped their price objective on Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a research report on Tuesday, April 21st. Finally, Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $118.67.

Abbott Laboratories Trading Down 0.5%

Shares of Abbott Laboratories stock opened at $110.68 on Tuesday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The business's fifty day moving average is $98.08 and its two-hundred day moving average is $99.79. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a market cap of $191.52 billion, a PE ratio of 35.82, a P/E/G ratio of 2.15 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the firm posted $1.26 earnings per share. The business's quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source